title: Ovarian cancer and DNA repair: DNA ligase IV as a potential key.
abstract: Ovarian cancer (OC) is the sixth most common cancer and the seventh cause of death from cancer in women. The etiology and the ovarian carcinogenesis still need clarification although ovulation may be determinant due to its carcinogenic role in ovarian surface epithelium. The link between ovarian carcinogenesis and DNA repair is well established and it became clear that alterations in DNA damage response may affect the risk to develop OC. Polymorphisms are variations in the DNA sequence that exist in normal individuals of a population and are capable to change, among other mechanisms, the balance between DNA damage and cellular response. Consequently, genetic variability of the host has a great role in the development, progression and consequent prognosis of the oncologic patient as well as in treatment response. Standard treatment for OC patients is based on cytoreductive surgery, followed by chemotherapy with a platinum agent and a taxane. Although 80% of the patients respond to the first-line therapy, the development of resistance is common although the mechanisms underlying therapy failure remain mostly unknown. Because of their role in oncology, enzymes involved in the DNA repair pathways, like DNA Ligase IV (LIG4), became attractive study targets. It has been reported that variations in LIG4 activity can lead to a hyper-sensitivity to DNA damage, deregulation of repair and apoptosis mechanisms, affecting the susceptibility to cancer development and therapy response. To overcome resistance mechanisms, several investigations have been made and the strategy to target crucial molecular pathways, such as DNA repair, became one of the important areas in clinical oncology. This review aims to elucidate the link between DNA repair and OC, namely which concerns the role of LIG4 enzyme, and how genetic polymorphisms in LIG4 gene can modulate the activity of the enzyme and affect the ovarian carcinogenesis and treatment response. Moreover, we try to understand how LIG4 inhibition can be a potential contributor for the development of new cancer treatment strategies.
authors.affiliation: Joana Assis, Rui Medeiros, Molecular Oncology GRP-CI, Portuguese Institute of Oncology, 4200-072 Porto, Portugal.
authors.forename: Joana
authors.initials: J
authors.lastname: Assis
authors.forename: Deolinda
authors.initials: D
authors.lastname: Pereira
authors.forename: Rui
authors.initials: R
authors.lastname: Medeiros
keywords: DNA Repair; DNA ligase IV; Ovarian Cancer; Polymorphisms; Susceptibility; Treatment response
references.citation: Nat Biotechnol. 2009 Sep;27(9):784-6
references.pmid: 19741614
references.citation: Endocr Rev. 2001 Apr;22(2):255-88
references.pmid: 11294827
references.citation: J Clin Oncol. 2003 Sep 1;21(17):3194-200
references.pmid: 12860964
references.citation: N Engl J Med. 2003 Feb 6;348(6):538-49
references.pmid: 12571262
references.citation: Cancer Res. 2002 Nov 15;62(22):6395-9
references.pmid: 12438222
references.citation: Hum Mol Genet. 2004 Oct 15;13(20):2369-76
references.pmid: 15333585
references.citation: Curr Biol. 1998 Jul 16;8(15):873-6
references.pmid: 9705934
references.citation: Am J Surg Pathol. 2004 Feb;28(2):147-59
references.pmid: 15043303
references.citation: Am J Pathol. 2004 May;164(5):1511-8
references.pmid: 15111296
references.citation: Am J Obstet Gynecol. 1975 Dec 1;123(7):772-4
references.pmid: 1200073
references.citation: Oncogene. 2003 Oct 20;22(47):7265-79
references.pmid: 14576837
references.citation: Nat Rev Genet. 2006 Jan;7(1):45-54
references.pmid: 16369571
references.citation: J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67
references.pmid: 10469746
references.citation: Clin Cancer Res. 2010 Jul 15;16(14):3706-12
references.pmid: 20606038
references.citation: Cell Res. 2006 Jan;16(1):45-54
references.pmid: 16467875
references.citation: J Cell Physiol. 2007 Nov;213(2):475-83
references.pmid: 17492771
references.citation: Hum Mol Genet. 2002 Jun 1;11(12):1399-407
references.pmid: 12023982
references.citation: Acta Oncol. 2008;47(5):809-24
references.pmid: 18568480
references.citation: DNA Repair (Amst). 2006 Sep 8;5(9-10):1042-8
references.pmid: 16822724
references.citation: Eur J Cancer. 2010 Mar;46(4):765-81
references.pmid: 20116997
references.citation: Cell Mol Life Sci. 2000 Aug;57(8-9):1229-35
references.pmid: 11028915
references.citation: Pharmacogenomics J. 2010 Dec;10(6):465-77
references.pmid: 20921971
references.citation: Cancer Res. 2004 Jul 15;64(14):5013-9
references.pmid: 15256476
references.citation: Mol Cell. 1998 Oct;2(4):477-84
references.pmid: 9809069
references.citation: Cancer Biol Ther. 2002 Sep-Oct;1(5):477-85
references.pmid: 12496472
references.citation: Cancer. 2012 Jan 15;118(2):528-35
references.pmid: 21717429
references.citation: Cancer Chemother Biol Response Modif. 1999;18:144-51
references.pmid: 10800481
references.citation: Pol J Pathol. 2010;61(1):27-31
references.pmid: 20496270
references.citation: Cancer. 2009 Jul 1;115(13):2939-48
references.pmid: 19408343
references.citation: Int J Cancer. 2005 May 1;114(5):730-7
references.pmid: 15609317
references.citation: Curr Biol. 1997 Aug 1;7(8):588-98
references.pmid: 9259561
references.citation: Lancet. 1971 Jul 17;2(7716):163
references.pmid: 4104488
references.citation: Ann Oncol. 2006 Apr;17(4):668-75
references.pmid: 16407418
references.citation: Cancer Sci. 2010 Aug;101(8):1881-5
references.pmid: 20487264
references.citation: Reproduction. 2002 Jun;123(6):743-50
references.pmid: 12052228
references.citation: Cancer. 2003 May 15;97(10 Suppl):2631-42
references.pmid: 12733128
references.citation: Carcinogenesis. 2004 Feb;25(2):189-95
references.pmid: 14578164
references.citation: Cochrane Database Syst Rev. 2010 Jun 16;(6):CD007929
references.pmid: 20556786
references.citation: Obstet Gynecol. 2006 Jun;107(6):1399-410
references.pmid: 16738170
references.citation: Genome Res. 1998 Dec;8(12):1229-31
references.pmid: 9872978
references.citation: J Oncol. 2010;2010:932371
references.pmid: 19746182
references.citation: Mol Oncol. 2009 Apr;3(2):171-81
references.pmid: 19383379
references.citation: J Natl Cancer Inst. 1998 Dec 2;90(23):1774-86
references.pmid: 9839517
references.citation: J Clin Oncol. 2008 Nov 10;26(32):5284-93
references.pmid: 18854563
references.citation: Oncologist. 2009 Jul;14(7):706-16
references.pmid: 19592450
references.citation: Nature. 1997 Apr 24;386(6627):761, 763
references.pmid: 9126728
references.citation: PLoS One. 2010 Apr 08;5(4):e10061
references.pmid: 20386703
references.citation: Swiss Med Wkly. 2012 Apr 27;142:w13550
references.pmid: 22544433
references.citation: DNA Repair (Amst). 2004 Aug-Sep;3(8-9):781-96
references.pmid: 15279764
references.citation: J Mol Biol. 2003 Nov 21;334(2):215-28
references.pmid: 14607114
references.citation: Int J Cancer. 2010 Dec 15;127(12):2893-917
references.pmid: 21351269
references.citation: Biochem Biophys Res Commun. 2009 Oct 2;387(4):656-60
references.pmid: 19615340
references.citation: Biochem Biophys Res Commun. 2006 Feb 3;340(1):256-62
references.pmid: 16364249
references.citation: Gene. 2012 Aug 10;504(2):279-83
references.pmid: 22634097
references.citation: Cancer Res. 2002 Jun 1;62(11):3052-7
references.pmid: 12036913
references.citation: J Mol Biol. 2003 Feb 7;326(1):93-103
references.pmid: 12547193
references.citation: Biochem Biophys Res Commun. 2005 Oct 7;335(4):1173-8
references.pmid: 16112085
references.citation: Essays Biochem. 1999;34:191-211
references.pmid: 10730196
references.citation: Cancer Res. 2008 May 1;68(9):3169-77
references.pmid: 18451142
references.citation: DNA Repair (Amst). 2007 Jun 1;6(6):712-22
references.pmid: 17241822
references.citation: Trends Biochem Sci. 1998 Oct;23(10):394-8
references.pmid: 9810228
references.citation: Nat Rev Cancer. 2009 Jun;9(6):415-28
references.pmid: 19461667
references.citation: Mutat Res. 1998 Feb;407(1):1-9
references.pmid: 9539976
references.citation: Mol Cell Endocrinol. 2006 Mar 9;247(1-2):4-21
references.pmid: 16297528
references.citation: Nature. 2001 Feb 15;409(6822):822-3
references.pmid: 11236997
references.citation: Br J Cancer. 2009 Jan 27;100(2):412-20
references.pmid: 19127255
references.citation: Hum Mutat. 2008 Mar;29(3):381-9
references.pmid: 18165945
references.citation: Toxicology. 2003 Nov 15;193(1-2):3-34
references.pmid: 14599765
references.citation: J Clin Oncol. 2010 May 10;28(14):2467-74
references.pmid: 20368557
references.citation: Mol Cell Biol. 1995 Jun;15(6):3206-16
references.pmid: 7760816
references.citation: Mol Microbiol. 1995 Aug;17(3):405-10
references.pmid: 8559059
references.citation: FEBS Lett. 2010 Sep 10;584(17):3703-8
references.pmid: 20691183
references.citation: Bioessays. 2003 Nov;25(11):1061-70
references.pmid: 14579247
references.citation: Breast Cancer Res Treat. 2010 Jan;119(1):201-11
references.pmid: 19360465
references.citation: Nat Struct Biol. 2001 Dec;8(12):1015-9
references.pmid: 11702069
references.citation: EMBO J. 1998 Sep 15;17(18):5497-508
references.pmid: 9736627
references.citation: Curr Biol. 1999 Jul 1;9(13):699-702
references.pmid: 10395545
references.citation: DNA Cell Biol. 2012 Jul;31(7):1182-6
references.pmid: 22413803
references.citation: Gene. 1999 Jul 8;234(2):177-86
references.pmid: 10395891
references.citation: Cancer. 1999 Dec 1;86(11 Suppl):2517-24
references.pmid: 10630177
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387
references.citation: Cell Cycle. 2009 Jun 15;8(12):1872-6
references.pmid: 19440052
references.citation: Cancer Chemother Pharmacol. 2010 Aug;66(3):501-6
references.pmid: 19960343
references.citation: Nucleic Acids Res. 2007;35(11):3535-50
references.pmid: 17483520
references.citation: Genome Biol. 2002;3(4):REVIEWS3005
references.pmid: 11983065
references.citation: Nature. 1997 Jul 31;388(6641):495-8
references.pmid: 9242411
references.citation: Lancet. 2009 Oct 17;374(9698):1371-82
references.pmid: 19793610
references.citation: Mol Biol Cell. 2008 Aug;19(8):3283-9
references.pmid: 18508926
references.citation: Lancet Oncol. 2008 Nov;9(11):1108-11
references.pmid: 19012860
references.citation: Biotechniques. 2005 Oct;39(10 Suppl):S565-8
references.pmid: 18957038
references.citation: Int J Gynecol Pathol. 2008 Apr;27(2):151-60
references.pmid: 18317228
references.citation: Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12109-13
references.pmid: 11593023
references.citation: Acta Biochim Pol. 2003;50(4):891-908
references.pmid: 14739985
references.citation: Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1323-31
references.pmid: 19616740
references.citation: J Clin Oncol. 2003 May 15;21(10 Suppl):149s-167s
references.pmid: 17633784
references.citation: Mutat Res. 1996 Aug 17;355(1-2):13-40
references.pmid: 8781575
references.citation: J Oncol. 2010;2010:314326
references.pmid: 20111741
references.citation: Mutat Res. 2000 Aug 30;460(3-4):301-18
references.pmid: 10946235
references.citation: Int J Clin Oncol. 2003 Jun;8(3):156-61
references.pmid: 12851839
references.citation: Annu Rev Biochem. 2008;77:313-38
references.pmid: 18518823
references.citation: Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10
references.pmid: 10883018